Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sobi
Biotech
Sobi pays $950M upfront to snap up gout specialist Arthrosi
Fresh off a series E round, Arthrosi is skipping an IPO route and is instead being bought up for a potential value of $1.5 billion from Sobi.
Ben Adams
Dec 15, 2025 8:15am
Selecta, Sobi rout gout in phase 3 trials to take on Horizon
Mar 21, 2023 7:40am
New federal biotech commission taps 12 members—Chutes & Ladders
Feb 3, 2023 10:20am
Sanofi offers up more Hemlibra rival data as FDA decision looms
Jan 26, 2023 9:40am
Sanofi gets FDA priority review for hemophilia A candidate
Aug 30, 2022 9:20am
Sanofi's Hemlibra rival gets FDA breakthrough tag
Jun 1, 2022 10:51am
